2 active not recruiting, 1 recruiting. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 2, Recruiting 1 |
Follow Volrustomig: new trials by email Literature Review of Volrustomig trials Research Report on Volrustomig
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC Volrustomig, Casdatifan - Advanced Clear Cell Renal Cell Carcinoma | Phase 1 | Active not recruiting | AstraZeneca | 9 | 2025-07-28 | 2026-08-03 |
| Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC T-DXd, Durvalumab, Cisplatin - Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Phase 1 | Recruiting | AstraZeneca | 304 | 2021-03-09 | 2026-04-13 |
| Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer Datopotamab deruxtecan, Durvalumab, Carboplatin - Advanced or Metastatic NSCLC | Phase 1 | Active not recruiting | AstraZeneca | 155 | 2021-02-02 | 2026-10-27 |
Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Renal Cell (1) · Diabetes Mellitus, Insulin-Dependent, 12 (1) · Kidney Neoplasms (1)
AstraZeneca (3)
Australia (2) · Belgium (2) · Italy (2) · Poland (2) · South Korea (2) · Spain (2) · Taiwan (2) · Turkey (Türkiye) (2) · United States (2) · Brazil (1) · Canada (1) · China (1) · France (1) · Israel (1) · Japan (1)
2023 (2)